Who is sponsoring NCT04756427?

NCT04756427 is sponsored by Johns Hopkins University.

What drugs are being tested in NCT04756427?

Interventions in NCT04756427: Sodium Citrate 4% Inj Syringe 3Ml.

What condition does NCT04756427 study?

NCT04756427 studies CLABSI - Central Line Associated Bloodstream Infection.

Is NCT04756427 still recruiting?

NCT04756427 is currently terminated. Last updated 19 September 2024.

Are results published for NCT04756427?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-09-19 · How we verify

NCT04756427

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sodium Citrate 4% Locking Solution for Children Requiring Home Parenteral Nutrition

Terminated Phase 4 Results posted Last updated 19 September 2024

What this trial tests

Phase 4 trial testing Sodium Citrate 4% Inj Syringe 3Ml in CLABSI - Central Line Associated Bloodstream Infection in 1 participant. Terminated before completion.

Timeline

28 March 2022

Primary endpoint
28 November 2023

28 November 2023

Quick facts

Lead sponsor	Johns Hopkins University
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	1
Start date	28 March 2022
Primary completion	28 November 2023
Estimated completion	28 November 2023
Sites	1 location across United States

Drugs / interventions tested

Sodium Citrate 4% Inj Syringe 3Ml — full drug profile →

Conditions studied

CLABSI - Central Line Associated Bloodstream Infection — all drugs for CLABSI - Central Line Associated Bloodstream Infection →

Sponsor

Johns Hopkins University

Who can join

Under 18, any sex, with CLABSI - Central Line Associated Bloodstream Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study an open label prospective observational cohort study to evaluate the safety and efficacy of sodium citrate 4% locking solution in preventing central line associated blood stream infection in children requiring long term central venous catheters for home parenteral nutrition. Sodium citrate 4% is FDA-approved for dialysis catheters, but has not been formally evaluated for use in tunneled catheters for parenteral nutrition. The rate of central line-associated bloodstream infection (CLABSI) and other potential adverse events will be monitored for 12 months, with the option to remain in the study for a longer period of time.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for CLABSI - Central Line Associated Bloodstream Infection

Currently open trials in the same condition.

NCT07255105 — Epidemiological Investigation of Central Venous Catheter-related Bloodstream Infections in Icus in China · recruiting
NCT06365528 — Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes · NA · recruiting
NCT06085690 — Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science · NA · recruiting

Other Johns Hopkins University trials

Trials by the same sponsor.

NCT06236542 — Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety · NA · not yet recruiting
NCT07532252 — Daridorexant for Alcohol Use Disorder · Phase 2 · not yet recruiting
NCT06687655 — Impact of Exogenous Ketones on Sleep Apnea · Phase 1, PHASE2 · not yet recruiting
NCT07079111 — 3D Printed Occlusal Splints for Intraoperative Use · NA · not yet recruiting
NCT02998502 — The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04756427 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins University
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04756427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing